METTL3, acting as the key component of the N6‐methyltransferase complex, was also reported to be highly expressed in other human cancers,16 which prompted us to investigate its role in regulating m6A modification of PCAT6. We treated PCa cells with siRNA targeting METTL3 (Figure 7C) and found that METTL3 silencing dramatically decreased m6A and expression level of PCAT6 in PCa cells (Figure 7D and E). The gene discussed is METTL3; the disease is posterior cortical atrophy.